Result of AGM

RNS Number : 5097L

Hikma Pharmaceuticals Plc

30 April 2020

 

Hikma Pharmaceuticals PLC

Voting Results of 2020 Annual General Meeting

LONDON, 30 April 2020 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated Ba1/stable Moody's and BB+/positive S&P) announces its Annual General Meeting ("AGM"), held at 22 Regent Road, Surbiton KT5 8NL on 30 April 2020 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 18 were passed as ordinary resolutions and Resolutions 19 to 22 were passed as special resolutions.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 26 February 2020) is set out below. The number of Ordinary Shares in issue on 30 April 2020 was 242,543,355.

Resolution	Votes For	%	Votes Against	%	Total Cast	Withheld
1. To receive the 2019 report and accounts	201,698,273	99.99	57	0.01	201,698,330	1,120,694
2. To approve a final dividend of 30 cents per share	202,811,365	99.99	6,764	0.01	202,818,129	895
3. To re-appoint PricewaterhouseCoopers LLP as auditors	202,808,789	99.99	8,990	0.01	202,817,779	1,245
4. To authorise the Audit Committee to determine the auditors' remuneration	202,814,187	99.99	3,664	0.01	202,817,851	1,173
5. To elect Cynthia Schwalm as a director	201,548,814	99.37	1,268,304	0.63	202,817,118	1,906
6. To re-elect Said Darwazah as a director	196,190,726	96.77	6,538,997	3.23	202,729,723	89,301
7. To re-elect Siggi Olafsson as a director	200,700,552	98.96	2,117,034	1.04	202,817,586	1,438
8. To re-elect Mazen Darwazah as a director	197,442,264	97.35	5,375,322	2.65	202,817,586	1,438
9. To re-elect Robert Pickering as a director	196,820,454	97.04	5,996,664	2.96	202,817,118	1,906
10. To re-elect Ali Al-Husry as a director	199,416,313	98.32	3,401,273	1.68	202,817,586	1,438
11. To re-elect Patrick Butler as a director	199,744,398	98.48	3,073,188	1.52	202,817,586	1,438
12. To re-elect Dr. Pamela Kirby as a director	195,639,660	96.46	7,177,925	3.54	202,817,585	1,438
13 . To re-elect Dr. Jochen Gann as a director	199,704,876	98.47	3,112,710	1.53	202,817,586	1,438
14 . To re-elect John Castellani as a director	199,425,273	98.80	2,426,100	1.20	201,851,373	967,651
15 . To re-elect Nina Henderson as a director	200,433,121	98.82	2,384,465	1.18	202,817,586	1,438
16. To approve the remuneration policy	190,931,576	95.50	8,992,802	4.50	199,924,378	2,894,646
17. To approve the remuneration report for the year ended 31 December 2019	190,252,825	95.16	9,671,582	4.84	199,924,407	2,894,616
18. Authority to allot shares	177,783,521	87.66	25,033,088	12.34	202,816,609	2,415
19 . To dis-apply pre-emption rights for general purposes	202,778,888	99.98	37,721	0.02	202,816,609	2,415
20. To dis-apply pre-emption rights for an acquisition or other capital investment	201,813,423	99.51	1,003,156	0.49	202,816,579	2,445
21. To authorise the Company to purchase its own shares	201,634,579	99.44	1,133,921	0.56	202,768,500	50,524
22. To authorise the Company to hold general meetings on no less than 14 clear days' notice	197,970,909	97.61	4,846,842	2.39	202,817,751	1,273

Declaration of final dividend

The dividend of 30 cents per share will be paid on 7 May 2020 to shareholders on the register on 20 March 2020.  Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling.  The exchange rate in respect of this dividend will be $1.238806 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	[phone]
Susan Ringdal EVP, Strategic Planning and Global Affairs	[phone]

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit:  www.hikma.com .

 

END

 

 

RAGSDIFSSESSEIL